Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Report from C&E News | Main | Maitotoxin Revisited »

April 26, 2010

Charles River Buys WuXi

Email This Entry

Posted by Derek

I don't think we saw this one coming: Charles River Labs has announced that they're buying WuXi PharmaTech. They're paying about a 28% premium over Friday's closing stock price - Charles River's CEO will stay on, and WuXi's founder (Li Ge) will serve as executive VP under him.

Charles River, which is strong in the animal-testing end of the business, has apparently decided that Wu Xi is one of their biggest competitors (I'd agree) and has decided to try to stake out a leading position in the whole contract-research space. It's interesting to me that the folks at Wu Xi bought into this reasoning as well, although (since they're a publicly traded company here in the US), a lucrative stock offer can be its own argument. One now wonders, though, about the company's statements on re-staffing some of their US labs when economic conditions improve. . .

Comments (15) + TrackBacks (0) | Category: Animal Testing | Business and Markets | Drug Assays | Drug Development


COMMENTS

1. RB Woodweird on April 26, 2010 9:38 AM writes...

Charles River: 777 employees, about $300 million revenue in 2009.
Wu Xi: (according to NYT) 4000 employees, $270 million revenue.

What is the policy in China re terminations? I know of some companies in which business units have branches in the US and also in countries where it is virtually impossible to lay anyone off. So when headcount is to be reduced, guess where the hatchet falls?

Permalink to Comment

2. mikeymedchem on April 26, 2010 10:01 AM writes...

Stunning. Absolutely.

Permalink to Comment

3. John on April 26, 2010 10:20 AM writes...

Bob, I think your numbers are just for the preclinical research services? The 2009 CRL annual report lists 8000 employees and $1.2B revenue. So CRL gets about twice as much revenue per employee as Wuxi (no surprise here).

CRL has an announced strategy of becoming a one stop shop for outsourced pharmaceutical research services, so I am inclined to see this as a move to pick up discovery chemistry, something they have had little or no capacity in previoiusly. But I could not readily find any info on what percentage of Wuxi's revenue comes from chemistry these days. Anybody know?

Permalink to Comment

4. Mike on April 26, 2010 1:15 PM writes...

It's funny that on the WuXi website it does not mention the Charles River is buying WuXi pharmatech, but rather the two companies are 'combining'.

"CHARLES RIVER LABORATORIES AND WUXI PHARMATECH TO COMBINE, CREATING THE FIRST GLOBAL CRO OFFERING FULLY INTEGRATED EARLY-STAGE DRUG DEVELOPMENT SERVICES TO CLIENTS WORLDWIDE"

http://ir.wuxipharmatech.com/phoenix.zhtml?c=212698&p=irol-news&nyo=0

Permalink to Comment

5. jon on April 26, 2010 6:33 PM writes...

This will be a disaster for CRL. The fact that Wuxi took the first offer means they will cash in and be gone as soon as their obligations under the purchase agreement are over, and CRL will be stuck trying manage a massive operation in China. Good luck with that. Any big pharma bean counter will tell you when a pharma company buys or sets up a Chinese operation, but the time they instill all of the culture and beauracracy of a US/European company, there is no price advantage. Just a language barrier and a very long plane flight

Permalink to Comment

6. You're Pfizered on April 27, 2010 10:50 AM writes...

I'm surprised this hasn't garnered more posts here, given the way the industry is moving, and WuXi's role therein.

Wonder what this means for over-all costs for their services. CRL can't really afford to hike the prices up too much, not with the competition they've got.

Permalink to Comment

7. milkshake on April 27, 2010 11:17 AM writes...

wonder if Charles River is planning to have a try at their own medchem research...

Permalink to Comment

8. pc on April 27, 2010 1:04 PM writes...

Costs, especially labor costs though still way below western standards, are rising there. RMB will likely gradually appreciate as well. Their competitiveness brought by low costs is diminishing, albeit still attractive at the moment. Maybe these folks are cashing out this way. Look for them trying to get their hands on the real deal, drug R&D that is, in the not-too-distant future. It's a gold mine, with the backing from government.

Permalink to Comment

9. noname on April 27, 2010 4:27 PM writes...

This move surprised me. I always predicted WuXi would be the kernel of the first major indigenous Chinese pharma company, with the financial backing of some giant Chinese conglomerate. The PRC government wants an innovative native biopharm industry. That is why they've encouraged both the CRO model and the creation of Chinese R&D branches of BigPharma. All this expertise was supposed to lead to the creation of Chinese pharma, and WuXi I thought was a candidate for this next step. This move, I believe, is a blow to that vision, insofar as I don't see CRL radically changing its business model. Maybe PRC will continue as a service center for another decade before it begins to find its own drugs for international market. Its too bad really, because the eventual transformation from service to internal development will narrow the outsourcing cost saving.

Permalink to Comment

10. PorkPieHat on April 27, 2010 7:54 PM writes...

I share the same sentiments as "noname". Both the Bioduro purchase by PPD and WuXi's purchase by CRL were surprising for the same reasons...opportunities for service companies to go solo in drug discovery and development. This model of service model to independent provider model has worked in the IT, energy and automobile sectors in China, among others. Could this mean some sort of PRC government takeover being sensed by these companies at some point soon? Are the principals in the companies taking their exit while they can? And what will these acquisitions do to what were robust US-based service providers for our industry?

Permalink to Comment

11. processchemist on April 28, 2010 2:51 AM writes...

An hypothesis: the building of a number of native CROs is maybe marginal in reaching the target of a chinese big pharma player, because of the low associated technology acquisition - in my experience the flow of technology is usually from the outsourcing partner to customer. Chinese structures of western big pharma or other western companies maybe are perceived as more effective in bringing know how in China (I've seen some leads buyed in China from small western biotechs: not impressive at all, to put it gently).

Permalink to Comment

12. Xu Li on May 3, 2010 7:54 PM writes...

Dr Ge Li is a brilliant man who turned around the CRO industry. In a short span of 10 years he built a company to rival the largest US CRO companies. This is not a small feat. It will make entrepreneurs like us leap to great heights. Why are the US companies doing so badly. Its because of poor management and greed from Senior executives. The US has lost its advantage and will cease to be a superpower.

Permalink to Comment

13. Fidel on May 3, 2010 7:56 PM writes...

In a span of 10 years Dr Ge Li built a $1.6 billion company employing 4000 people. In the same time Derek Lowe fiddled away his time

Permalink to Comment

14. Vanesa Sae on January 7, 2013 4:16 PM writes...

I am curious to find out what blog platform you are utilizing? I'm having some small security issues with my latest blog and I'd like to find something more secure. Do you have any solutions?

Permalink to Comment

15. Grisel Tokay on March 29, 2014 1:33 PM writes...

here comes the bride banner pictures

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Most Common Heterocycles in Drugs
Eric Betzig Is Not a Chemist, And I Don't Much Care
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored